文献速递淋巴瘤造血干细胞移植与细胞治疗

桥接治疗后达完全缓解的复发难治DLBCL患者接受替沙来塞治疗的疗效与安全性

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
PubMed 文献 · Blood Adv · 2019-01-01

该研究基于JULIET试验,分析7例复发难治弥漫大B细胞淋巴瘤(r/r DLBCL)患者在桥接治疗后、替沙来塞输注前达完全缓解(CR)的亚组。替沙来塞在全部7例中快速扩增,输注后3个月时7例均维持CR,5/7例无进展生存超过12个月。安全性总体与JULIET总人群相似,细胞因子释放综合征(CRS)发生于4/7例(Penn分级2级2例、3级2例),1例发生1级神经毒性,无患者需托珠单抗或激素处理CRS。

要点

  • 7例桥接后达CR的r/r DLBCL患者输注替沙来塞后3个月均维持CR。
  • 5/7例患者无进展生存超过12个月,替沙来塞在全部7例中快速扩增。
  • CRS发生于4/7例(2级2例、3级2例),1例1级神经毒性,无需托珠单抗或激素。

核心结论

  • 替沙来塞在桥接或挽救治疗后无可检测病灶的r/r DLBCL患者中显示出初步疗效证据,值得在未来试验中进一步研究其作为巩固治疗的作用。

研究设计与样本

  • 基于JULIET试验(NCT02445248)的亚组分析,纳入7例桥接治疗后、替沙来塞输注前达完全缓解(CR)的r/r DLBCL患者。

主要发现

  • 替沙来塞在全部7例患者中快速扩增,转基因水平在输注后长达2年内可测。
  • 输注后3个月评估时,全部7例患者仍维持CR;7例中5例无进展生存超过12个月。
  • 不良事件与JULIET总人群相似;CRS发生于4/7例(Penn分级2级2例、3级2例),1例发生1级神经毒性。
  • 无患者因CRS管理需要托珠单抗或激素。

关键数值与推荐

  • JULIET试验中大多数患者(92%)在研究入组后、替沙来塞输注前接受桥接治疗以控制疾病。
  • 本亚组7例患者在桥接治疗后、替沙来塞输注前达到CR。
  • CRS采用Penn分级:2级2例、3级2例;神经毒性1级1例。

临床怎么用

  • 原文指出这些数据为替沙来塞在桥接或挽救治疗后无可检测病灶的r/r DLBCL患者中的疗效提供了初步证据。
  • 原文提出值得在未来试验中进一步研究替沙来塞作为巩固治疗的作用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies to control disease after study entry and before tisagenlecleucel infusion. Here, we examine the efficacy and safety of tisagenlecleucel in the subset of 7 patients who achieved complete response (CR) after bridging therapy and before tisagenlecleucel infusion. Tisagenlecleucel rapidly expanded in all 7 patients, and the transgene levels were measurable for up to 2 years after infusion. After infusion, all 7 patients were still in CR at the month 3 evaluation, and 5 of 7 patients remained progression-free >12 months. Adverse events were similar to the overall JULIET population. Cytokine release syndrome (CRS) was reported in 4 of 7 patients (grade 2 = 2 and grade 3 = 2 using the Penn grading scale), and 1 patient experienced grade 1 neurotoxicity. No patient required tocilizumab or steroids for CRS management. These data provide preliminary evidence of tisagenlecleucel efficacy in patients with r/r DLBCL without detectable disease after bridging or salvage therapies and warrant further investigation of tisagenlecleucel as consolidative therapy in future trials. This trial was registered at www.clinicaltrials.gov as #NCT02445248.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bishop MR, Maziarz RT, Waller EK, et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019. PMID: 31332046. doi:10.1182/bloodadvances.2019000151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。